Antimicrobials cost as much to develop as other drugs, but don’t earn the same returns. Congress could give drugmakers a boost, but time is running out.Thanks for listening to WIRED. Check back in tomorrow to hear more stories from WIRED.com.

The latest in-depth coverage covering the intersection of technology and culture. WIRED’s award-winning journalism will help you make sense of a world in constant transformation. Join us as we explore the ways technology is changing our lives.

Advertisement